Practice Points Developed for Treatment of Outpatient COVID-19
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 20, 2023 -- In an updated clinical guideline issued by the American College of Physicians and published online Sept. 19 in the Annals of Internal Medicine, living, rapid practice points are presented for the outpatient treatment of confirmed COVID-19.
Amir Qaseem, M.D., Ph.D., from the American College of Physicians in Philadelphia, and colleagues developed living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically relating to the omicron variant.
The authors note that molnupiravir should be considered for treating symptomatic patients with confirmed mild-to-moderate COVID-19 in the outpatient setting who are within five days of symptom onset and who have a high risk for progression to severe disease. For symptomatic patients with mild-to-moderate COVID-19 in the outpatient setting who are within five days of symptom onset and have a high risk for progression to severe disease, nirmatrelvir-ritonavir combination therapy should also be considered. Ivermectin should not be used for patients with confirmed mild-to-moderate COVID-19 in the outpatient setting. Sotrovimab should also not be used for patients with confirmed mild-to-moderate COVID-19 in the outpatient setting.
"More research evaluating the efficacy, effectiveness, and comparative effectiveness, as well as harms, of pharmacologic and biologic treatments of COVID-19 in the outpatient setting is needed, particularly in the context of changing dominant severe acute respiratory syndrome coronavirus 2 variants and subvariants," the authors write.
One author disclosed financial ties to Eli Lilly.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Further Support and Information on COVID-19
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.